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 2 
SUMMARY 21 
It has been proposed that peptide epitopes bind to MHC class II molecules to form 22 
distinct structural conformers of the same MHC-II-peptide complex termed type A and 23 
type B, and that the two conformers of the same peptide-MHC-II complex are 24 
recognized by distinct CD4 T cells, termed type A and type B T cells. Both types 25 
recognise short synthetic peptides but only type A recognise endosomally processed 26 
intact antigen. Type B T cells that recognise self peptides from exogenously degraded 27 
proteins have been shown to escape negative selection during thymic development 28 
and so have the potential to contribute to the pathogenesis of autoimmunity.  29 
We generated and characterised mouse CD4 T cells specific for an arthritogenic 30 
epitope of the candidate joint autoantigen proteoglycan aggrecan. Cloned T cell 31 
hybridomas specific for a synthetic peptide containing the aggrecan epitope showed 32 
two distinct response patterns based on whether they could recognise processed  33 
intact aggrecan. Fine mapping demonstrated that both types of T cell recognised the 34 
same core epitope. The results are consistent with the generation of aggrecan-specific 35 
type A and type B T cells.  36 
Type B T cells were activated by supernatants released from degrading cartilage 37 
indicating the presence of antigenic extracellular peptides or fragments of aggrecan. 38 
Type B T cells could play a role in the pathogenesis of proteoglycan-induced arthritis 39 
in mice, a model for rheumatoid arthritis, by recognising extracellular peptides or 40 
protein fragments of joint autoantigens released by inflamed cartilage.  [238w]  41 
 3 
Introduction 42 
Soon after the discovery that TCR recognize peptides bound to MHC molecules (1,2), 43 
it was shown that the local environment influences the conformation adopted when 44 
peptides bound to MHC-II (3,4). On this background, the results of a study of HEL 45 
presentation by the Ak molecule suggested that MHC-II formed complexes with a 46 
single peptide in more than one conformation distinguishable by TCR (5-8). Similar 47 
observations were made for an Ek-restricted epitope of HEL (9), and for autoantigens, 48 
binding to a number of H-2 A and E alleles and to HLA DR1 (9-16). More detailed 49 
investigation showed that a proportion of T cells from mice immunized with a synthetic 50 
HEL peptide recognized the peptide in vitro but not processed intact HEL, whereas 51 
epitope specific T cells from HEL-immunized mice recognized both synthetic peptide 52 
and processed HEL (9,17). The data were interpreted as showing the formation of two 53 
conformers, termed type A and type B peptide-MHC-II complexes, recognized by CD4 54 
T cells termed type A and type B T cells with specificity for one or other conformer 55 
(reviewed in (18-20)). Subsequent studies have shown that peptide-MHC complex 56 
formation is influenced by the mechanism of generation of the peptide epitope, so that 57 
the type A conformers are generated after processing of intact proteins in acidic 58 
endosomal compartments of APC and loading of newly synthesized MHC-II under the 59 
control of the chaperone DM (21). Alternatively, exogenous peptides were shown to 60 
bind to mature MHC-II molecules in early endosomes or at the APC surface in the 61 
absence of functional DM resulting in formation of a mixture of type A and type B T 62 
conformers (21). Infection of mice with Salmonella typhimurium has also been shown 63 
to bias HEL presentation by dendritic cells towards a type B T cell response by a 64 
Dectin-1 dependent mechanism (22,23). Furthermore, mice expressing endogenous 65 
HEL were used to show that type B T cells escape negative selection during thymic 66 
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development in vivo, whereas the majority of type A T cells are deleted (24), creating 67 
a scenario in which self-reactive type B T cells could persist in peripheral lymphoid 68 
organs. Type B T cells specific for the autoepitope of insulin 9-23/Ag7 have been cloned 69 
from pancreatic islets, the site of autoimmune damage (16), and so localised where 70 
they could play a role in autoimmunity. However, the source of natural peptide ligands 71 
that preferentially activate type B T cells in autoimmune disease has not been 72 
reported.  73 
The major cartilage component proteoglycan aggrecan is a candidate autoantigen in 74 
inflammatory arthritis (25) and immunization of BALB/c mice with aggrecan in adjuvant 75 
induces an inflammatory arthritis mediated by CD4 T cells specific for the 76 
immunodominant arthritogenic epitope 84-103 (26). In addition, extracellular 77 
proteolysis is a characteristic of inflammatory arthritis, resulting from upregulation of 78 
matrix degrading metallo-proteinases and increased degradation of cartilage matrix 79 
components including aggrecan (27). Thus we reasoned that the T cell repertoire 80 
includes type B T cells that may recognise extracellular aggrecan fragments released 81 
during inflammation. Here we demonstrate both type A and type B patterns of 82 
recognition amongst CD4 T cell hybridomas specific for the same core epitope of 83 
aggrecan. We further show that aggrecan-specific type B T cells are activated by 84 
exogenous antigenic ligands released from degrading cartilage. The results are a step 85 
towards determining whether type B T cells participate in proteoglycan-induced 86 
arthritis in mice, and more generally whether they contribute to the pathogenicity of 87 
rheumatoid arthritis and other autoimmune disease in man. 88 
 89 
Materials and Methods  90 
Reagents  91 
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Proteoglycan aggrecan was purified from bovine nasal cartilage as previously 92 
described (28). The synthetic peptide 84VVLLVATEGRVRVNSAYQDK103 of bovine 93 
aggrecan includes the core arthritogenic CD4 T cell epitope 92GRVRVNSAY100 ((29) 94 
where the sequence is numbered 73-81), see the Immune Epitope Data Base epitope 95 
ID 107090, 132189 and 137285 at http://www.immuneepitope.org/. The sequence of 96 
the aggrecan epitope is identical in human (Acc. No. P16112) and bovine (Acc. No. 97 
P13608) aggrecan but differs from mouse aggrecan by two amino acids 98 
(92GQVRVNSIY100, Acc. No. Q61282). Aggrecan peptide 84-103, and the same 99 
peptide modified by substitution of citrulline for arginine at position 93 (93cit95R), 95 100 
(93R95cit) or both (93cit95cit) compared to the native sequence (93R95R), were 101 
purchased from JPT Peptide Technologies GmbH, Berlin, Germany. Peptides for fine 102 
mapping were purchased from Proimmune (Oxford, UK), and represent staggered 103 
peptides of 14 amino acids offset by 1 amino acid inclusive of the aggrecan sequence 104 
84-108, and peptides with alanine substituted sequentially at positions 90 to 103, 105 
except glycine substituted for the alanine at position 89.  106 
Bovine nasal cartilage and healthy human articular cartilage explants were prepared 107 
as described previously (30). Human cartilage from the femurs of rheumatoid arthritis 108 
patients undergoing surgery were obtained with local ethical approval. Briefly, cartilage 109 
was cut into 1 mm3 fragments and 0.5 g of fragments transferred to 5ml serum-free 110 
medium (RPMI-1640 with 2mM glutamine, 30 µg/ml gentamycin and 0.05mM 2-111 
mercaptoethanol) in wells of a 6 well plate. Plates were incubated in a humidified 112 
environment at 37ºC with 5% CO2. The serum free medium was changed after 24 113 
hours and 1 ng/ml of recombinant human IL-1α and 10 ng/ml human Oncostatin-M 114 
(gifts from Dr. K. Ray, Glaxo-Smith-Kline, Stevenage) were added (30). Plates were 115 
further incubated at 37ºC for up to 20 days and supernatants were removed and stored 116 
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at -30ºC prior to use in T cell hybridoma assays. 117 
 118 
Mice 119 
BALB/c mice were purchased from Charles River (Margate, UK) and the in vivo 120 
procedures described were performed under the terms of the Animals (Scientific 121 
Procedures) Act 1986 authorized by the Home Secretary, Home Office UK. Mice were 122 
immunized in one footpad with 25 g of aggrecan or synthetic peptide in Titermax 123 
adjuvant (Sigma-Aldrich, Gillingham, UK) and popliteal lymph nodes were removed 7 124 
d later for ex-vivo assay. 125 
 126 
Cells 127 
Culture medium reagents and other chemicals were purchased from Sigma-Aldrich 128 
(Gillingham, UK), unless otherwise stated. All cells were grown in culture medium 129 
consisting of RPMI 1640 containing 3 mM L-glutamine, 50 M 2-ME, 10% v/v FBS 130 
(BioSera, Ringmer, UK) and 30 g/ml gentamicin.  131 
Macrophages were grown from femoral bone marrow cells of BALB/c mice by culture 132 
in bacteriological Petri dishes for 6 days in culture medium supplemented with 1 mM 133 
sodium pyruvate, 5% horse serum and 5% of a supernatant from the L929 fibroblast 134 
cell line as a source of M-CSF as described previously (31). Cells were activated by 135 
treatment with 1 ng/ml IFN- (R&D Systems, Abingdon, UK) overnight at 37˚C in a 136 
humidified CO2 incubator and shown by flow cytometry to be at least 90% positive for 137 
expression of the macrophage marker F4/80.  138 
Dendritic cells (DC) were also grown from femoral bone marrow cells by culture for 10 139 
days in 6-well plates in culture medium supplemented with 20 ng/ml rGM-CSF, 140 
replenishing the supplemented medium every 3 days. Cells were then incubated with 141 
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0.2 µg/ml lipopolysaccharide to induce maturation, and shown by flow cytometry to be 142 
>80% DC for the dendritic cell marker CD11c.  143 
The H-2d expressing B lymphoma cell line A20 (TIB-208) and macrophage cell line 144 
J774A.1 (TIB-67), were obtained from ATCC.  145 
Stable T cell lines were derived from lymph node cells from peptide or aggrecan 146 
immunized BALB/c mice by 2 to 3 rounds of restimulation with synthetic 84-103 147 
peptide and irradiated spleen cells as APC, followed by expansion in rIL-2, before 148 
polyethylene glycol-mediated fusion with the TCRα-β- BW5147 leukaemic cell line, as 149 
described previously (32). The majority of T cell hybridomas were shown to respond 150 
to aggrecan peptide 84-103 and express CD4, CD3, and TCRαβ by flow cytometry. 151 
The following T cell hybridomas were used in this study: 2G9 (V8.3), 1271b (V8.2), 152 
1G2 (V8.3), 2D7 (V14). 153 
 154 
Lymph node proliferation assay 155 
Popliteal lymph nodes were removed 7 d after footpad immunisation of BALB/c mice. 156 
Popliteal lymph node cells were cultured in the presence or absence of a range of 157 
doses of aggrecan or synthetic peptides for 72 h at 3 x 105 per well in 96-well round 158 
bottom microtiter plates. 5 KBq per well of tritiated thymidine (NET027A005MC, sp. 159 
act. 0.074 TBq/mM, Perkin-Elmer, Cambridge, UK) was added for the final 16 h of 160 
culture before harvesting on glass fibre membranes. Radioactivity was quantitated 161 
using a liquid scintillation counter (Perkin Elmer Microbeta Trilux) and results are 162 
presented as mean cpm ± SEM. Responses two-fold above medium only controls 163 
were considered significant. 164 
 165 
T cell hybridoma assay 166 
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Antigen presenting cells (4 x 104/well macrophages, A20 B cells or DC) were plated in 167 
medium with or without a range of doses of aggrecan or synthetic peptide, or diluted 168 
cartilage explant supernatants in triplicate wells and incubated for 3 h. T cell hybridoma 169 
cells (4 x 104/well) were added and plates were incubated for a further 24 h and then 170 
frozen. Responses of T cell hybridomas were determined as the amount of IL-2 171 
released in a bioassay measuring proliferation of IL-2 dependent CTLL-2 cells. CTLL-172 
2 cells (3 x 104/well) were incubated in triplicate wells of flat-bottomed 96-well 173 
microtiter plates in the presence of T cell hybridoma culture supernatants diluted 1:2. 174 
Plates were incubated for 24 h and labelled with tritiated thymidine and results 175 
expressed as described for the lymph node proliferation assay above. Experiments 176 
were repeated no less than three times. 177 
 178 
Results 179 
Lymph node proliferation responses of aggrecan and peptide immunised mice 180 
BALB/c mice were immunised with bovine aggrecan or with the synthetic peptide 181 
representing amino acids 84-103 of aggrecan, containing the major arthritogenic CD4 182 
T cell epitope, and proliferation to aggrecan and peptide was recalled in vitro (Fig. 1). 183 
Mice immunized with aggrecan responded to both peptide and aggrecan to a similar 184 
extent, confirming the immunodominance of the response to the arthritogenic epitope 185 
contained within peptide 84-103 (Fig. 1a). Mice immunized with peptide responded to 186 
both peptide and aggrecan, but the response to peptide was of a greater magnitude 187 
(Fig 1b), suggesting more T cells responded to peptide alone than to both peptide and 188 
aggrecan. The specificity of response for the immunizing antigens was confirmed by 189 
the lack of response in HBSS immunized mice (Fig. 1a). One interpretation of the 190 
results is that peptide-immunisation induces two populations of peptide-specific T cells 191 
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differing in their ability to recognize processed aggrecan, reminiscent of the type A and 192 
type B T cell responses reported for epitopes of HEL (18). 193 
  194 
Patterns of recognition of T cell hybridomas to aggrecan and peptide 195 
To investigate further we cloned and immortalised T cells from peptide 84-103 196 
immunised mice and measured their responses to peptide and aggrecan. Of 23 84-197 
103-specific T cell hybridomas generated from peptide-immunized mice, 9 responded 198 
to peptide and aggrecan and 14 responded to peptide only, consistent with the 199 
generation of cloned T cells with type A and type B recognition patterns. Dose 200 
response titrations for presentation of aggrecan and peptide by bone marrow-derived 201 
macrophages, dendritic cells (DC) and immortalised A20 B cells to representative T 202 
cell hybridomas are shown in Fig. 2. T cell hybridomas 2G9 (Fig. 2a,e) and 1271b (Fig. 203 
2b,f) responded equally well to aggrecan and peptide when presented by either 204 
macrophages or DC, typical of type A T cells. T cell hybridomas 1G2 (Fig. 2c,g) and 205 
2D7 (Fig. 2d,h) responded to peptide but not to aggrecan presented by macrophages 206 
or DC over the same antigen dose range. Although A20 B cells process and present 207 
aggrecan less efficiently, the same pattern was still observed, in that T cell hybridomas 208 
2G9 and 1271b responded to peptide and aggrecan (figs. 2i,j), but hybridomas 1G2 209 
and 2D7 responded to peptide only (Fig. 2k,l). All four peptide specific hybridomas 210 
clearly showed one or other of the two recognition patterns, independent of the type 211 
of APC, with no intermediate patterns of response.  212 
 213 
Fine specificity of aggrecan epitope recognition 214 
To establish whether the patterns of recognition could be accounted for by the 215 
presence of more than one epitope within peptide 84-103, the fine specificity of type 216 
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A and type B T cell hybridomas was determined using overlapping peptides staggered 217 
by one amino acid (Fig. 3A), as well as peptides in which each position was serially 218 
substituted with alanine (Fig. 3B). T cell hybridomas 2G9, 1271b, 1G2 and 2D7 219 
differed in the requirement for the presence of particular amino acids of the core 220 
epitope and flanking amino acids (Fig. 3A), ranging from maximum response to 86-99 221 
to 92-105 staggered peptides (2G9) to maximum response to only 89-102 (2D7), but 222 
responses of all four T cell hybridomas tested centred on peptide 89-102.  223 
Fine specificity differences were also observed in the responses to serially alanine 224 
substituted peptides (Fig. 3B). A clear dependence on arginine at position 95 and 225 
asparagine at position 97 was observed, suggesting that the P4 and P6 MHC contact 226 
residues of the core epitope, defined previously as P1-P9 92GRVRVNSAY100 (29), is a 227 
common feature of all T cell hybridomas studied. Thus the response to staggered and 228 
substituted peptide sets showed that T cells with both the type A and type B recognition 229 
patterns focussed on a single core epitope binding to Ad in the same register.  230 
 231 
T cell hybridoma recognition of citrullinated aggrecan peptides 232 
Different patterns of recognition of the aggrecan epitope could result from post-233 
translational modifications such as citrullination of one or both of the arginines within 234 
the aggrecan 92GRVRVNSAY100 epitope as a result of the activity of peptidyl arginyl 235 
deaminases known to be present both within Rheumatoid synovium (33) and within 236 
the endosomal system of APC (34). We tested synthetic 84-103 peptides in which 237 
arginine at position 93 (93cit, P2 of the core epitope) or 95 (95cit, P4 of the core 238 
epitope), or both (93cit95cit), were substituted with citrulline, and compared 239 
recognition by type A and type B T cell hybridomas using the macrophage cell line 240 
J774A.1 as APC (Fig. 4). Both type A and type B hybridomas recognised the 241 
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unmodified peptide (93R95R) (Fig. 4). All hybridomas also recognized the peptide 242 
citrullinated at position 93, and both type A hybridomas, but neither type B, responded 243 
to the peptide citrullinated at position 95, all in the sub-micromolar dose range. None 244 
of the hybridomas recognised the doubly modified peptide 93cit95cit. The similar 245 
responses of all hybridomas to the peptide citrullinated at position 93, excludes the 246 
possibility that the different recognition patterns resulted from this post translational 247 
modification. The response of type A but not type B T cell hybridomas to the peptide 248 
citrullinated at position 95 could represent an alternative to conformational isomerism 249 
in explanation of type B recognition.  250 
 251 
T cell hybridoma recognition of supernatants from degrading cartilage 252 
Cartilage turnover is catalysed in vivo by metallo-proteinase enzymes that degrade 253 
aggrecan and other matrix components, the activity of which can be induced by the 254 
presence of inflammatory cytokines IL-1α and oncostatin-M (30). We recapitulated this 255 
milieu of degradation products in vitro by incubating bovine and human cartilage 256 
explants with these inflammatory cytokines and removing supernatants for use as 257 
antigen in T cell assays. Supernatants were added to antigen presentation assays with 258 
type A and type B T cell hybridomas and bone marrow macrophages as APC. Type A 259 
T cell hybridoma 1271b responded to doses of less than 1% of cartilage supernatants 260 
and responses increased proportional to the incubation time. Responses to 261 
supernatants reached the magnitude of the peptide control by 10 days of cartilage 262 
incubation (Fig. 5a), consistent with the kinetics of aggrecan release in this system 263 
(30). T cell hybridoma 1271b also responded optimally to doses of less than 1% of the 264 
three supernatants from degrading human cartilage, reaching the magnitude of the 265 
peptide control (Fig. 5b).  266 
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The two type B T cell hybridomas 1G2 and 2D7 also recognised supernatants from 267 
degrading bovine and human cartilage explants, but much less efficiently than the type 268 
A T cell hybridoma 1271b (Fig. 5a,b). Responses of both type B T cell hybridomas 269 
required doses greater than 1% of supernatant and cartilage incubation for 20 days, 270 
and were of a low magnitude compared to the peptide control (Fig. 5a). Both type B T 271 
cell hybridomas also responded to all three supernatants from degrading human 272 
cartilage (Fig. 5b). Despite the low magnitude of responses, the data suggest that 273 
aggrecan-derived type B ligands are released and available for presentation during 274 
cartilage degradation. Relatively small amounts of type B T cell ligands compared to 275 
intact aggrecan could stimulate type B T cells that have escaped thymic deletion, when 276 
type A T cells would be scarse due to their more complete deletion. 277 
 278 
Discussion 279 
We show here that T cell hybridomas specific for a major arthritogenic epitope of the 280 
cartilage component proteoglycan aggrecan express TCR that display recognition 281 
patterns characteristic of type A and type B T cells. This pattern has previously been 282 
defined for epitopes of HEL, cytochrome-c, Eα, Aβk, myelin basic protein and insulin, 283 
and includes epitopes binding to a range of mouse MHC class II A and E alleles as 284 
well as to HLA-DR1 (8-13,15,16,18,35). Our data is the first report of type B T cells 285 
restricted by Ad, and the first for type B T cell recognition of a candidate joint 286 
autoantigen. The number of different antigens and MHC alleles that have been studied 287 
suggest that type B T cell recognition is a universal property of TCR-peptide-MHC 288 
class II interactions. The most likely explanation for the different patterns of recognition 289 
is that type A and type B T cells recognise distinct conformational isomers of a single 290 
peptide-MHC complex (18), a conclusion supported by biochemical data (11,36-38), 291 
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but no x-ray crystallographic evidence to date. However, a similar recognition pattern 292 
could result from a number of alternative mechanisms (discussed in (18)): (i) 293 
Contamination of peptides during synthesis or storage leading to the presence of 294 
peptides of different specificities, although we have used freshly dissolved peptides 295 
obtained from more than one commercial supplier to minimise this possibility. (ii) Free 296 
N- or C-terminal amino acids flanking the epitope in shorter synthetic peptides dictating 297 
distinct patterns of TCR fine specificity, excluded here by the observation that type B 298 
T cells recognised a number of adjacent staggered peptides with different terminal 299 
amino acids. (iii) Post-translational modification of amino acids leading to distinct TCR 300 
specificities. We investigated the response of T cell hybridomas to the aggrecan 301 
peptide 84-103 modified by citrullination at position 93, 95 or both. The responses of 302 
type A and B T cells were similar to peptides citrullinated at position 93 or at positions 303 
93 and 95, but type A cross reacted with the peptide citrullinated at position 95 304 
whereas type B T cells did not. This could be a result of the reduced sensitivity of type 305 
B T cell recognition but is unlikely to explain the difference in type A and type B 306 
recognition.  All T cell hybridomas cross reacted between unmodified 84-103 and the 307 
peptide citrullinated at position 93, and none of the hybridomas recognised the doubly 308 
citrullinated peptide, so that citrullination could not explain the type A and type B T cell 309 
recognition patterns observed. (iv) Different populations of T cells specific for 310 
overlapping dominant and cryptic epitopes present on the same peptide, for which 311 
there are precedents (39-42), that would result in the differential recognition of intact 312 
protein by T cells against the two epitopes. The T cell hybridomas used here were 313 
shown to be specific for the same core aggrecan epitope 84-103 by fine mapping with 314 
staggered and substituted peptide sets, and only a single epitope was localised to this 315 
region in extensive epitope mapping of aggrecan in BALB/c mice (43). 316 
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As type B T cells recognise peptides but not intact protein antigens after intracellular 317 
processing, we propose that the peptide ligands required for type B T cell activation 318 
are generated by extracellular degradation during the inflammatory response. It is 319 
known that peptides in the extracellular milieu directly bind MHC class II on the APC 320 
surface (44) or in early endosomes (45-49). Treatment of DC with TLR ligands or IFN-321 
α in vitro (50) or their administration in vivo (51) leads to presentation of epitopes from 322 
intact proteins to type B T cells probably as a result of extracellular processing, 323 
although the mechanisms were not investigated. However, a source of natural ligands 324 
that activate type B T cells has not been previously reported. 325 
Hyaline cartilage turnover in healthy synovial joints is mediated by a family of metallo-326 
proteases, including aggrecanases, and these enzymes contribute to the cartilage loss 327 
observed in inflammatory arthritis (27). Extracellular matrix degradation products have 328 
been identified in synovial fluid from patients with arthritis (52-54), and fragments of 329 
collagen and hyaluronan have been shown to contribute to the inflammatory response 330 
(55). These extracellular antigenic fragments are presumed to be the basis for the 331 
proposal that 'remnant epitopes' are generated from cartilage components in the 332 
extracellular space that are then presented to T cells as a mechanism that perpetuates 333 
autoimmunity (56-58). Whether it is type A or type B T cells which participate in this 334 
response has not been investigated to date. We used bovine and human cartilage 335 
explants treated with pro-inflammatory cytokines to mimic cartilage loss during 336 
inflammatory arthritis, and showed that the supernatants generated could activate 337 
aggrecan-specific type B T cells, suggesting degrading cartilage releases aggrecan 338 
peptides that are available for presentation to type B T cells. The responses were 339 
detectable only after extended periods of incubation of cartilage explants and the 340 
magnitude of response was also low compared to the responses of type A T cells, the 341 
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latter probably reflecting recognition of processed intact aggrecan known to be 342 
released by degrading cartilage (52-54). The data suggest that type B T cell ligands 343 
are less abundant in degrading cartilage than intact aggrecan, and are more likely to 344 
be rapidly degraded. It has also been shown that capture and presentation of 345 
extracellular peptide epitopes by surface MHC class II is inefficient (45,59) but DM 346 
independent (47,48), and so would be permissive for type B T cell recognition. 347 
Type B T cells recognising exogenous self antigens have been suggested to persist 348 
in the periphery due to escape from negative selection during thymic development, 349 
circumstances in which type A T cells would be largely deleted. Consequently we 350 
propose that type B T cells recognizing cartilage antigens may represent a significant 351 
and even dominant contribution to the T cell response in autoimmune arthritis (15, 20). 352 
Increased turnover of cartilage due to chronic trauma or reactive inflammation caused 353 
by infection could release peptides or fragments from cartilage autoantigens above a 354 
threshold required for type B T cell activation. However, it remains to be determined 355 
whether type B T cells perform regulatory functions, provide help for pathogenic 356 
autoantibody responses, or differentiate into IFN- and IL-17 producing effector T cells 357 
implicated in joint damage in the animal models of arthritis, in RA in humans, and in 358 
other automimmune diseases.  359 
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Figure legends 577 
 578 
Figure 1. Lymph node responses to aggrecan and peptide. BALB/c mice were 579 
immunized with 25 μg aggrecan (a), or 100 μg peptide (b) in adjuvant, and 7 days later 580 
proliferation of PLN cells was assayed by tritiated thymidine incorporation in response 581 
to a dose range of peptide (circles) or aggrecan (triangles). Proliferation of PLN from 582 
HBSS-immunized mice was used as a negative control (open symbols in a), and 583 
responses of PLN to 5 μg/ml concanavalin A (con A) as a positive control (closed 584 
squares). Results are expressed as mean cpm ± SEM of 5 mice. 585 
 586 
Figure 2. T cell hybridoma responses to peptide and aggrecan. 4 x 104 per well of 587 
T cell hybridomas 2G9 (a,e,i), 1271b (b,f,j), 1G2 (c,g,k) or 2D7 (d,h,l) were incubated 588 
for 24 h with 4 x 104 per well of either bone marrow derived macrophages, bone 589 
marrow-derived DC, or the B lymphoma line A20 as APC, and a range of doses of 590 
aggrecan or aggrecan peptide 84-103. Responses were measured as cytokine release 591 
into the supernatant in a bioassay with IL-2 dependent CTLL-2 cells as described in 592 
Materials and Methods, and results are shown as cpm ± SEM for triplicate wells for a 593 
representative of at least two different experiments for each hybridoma.  594 
 595 
Figure 3. Fine mapping T cell hybridoma responses to peptide. T cell hybridomas 596 
2G9, 1271b, 1G2 and 2D7 were assayed for responses to 10 M doses of the 597 
staggered (row A) or alanine substituted (row B) peptides shown, using bone marrow 598 
derived macrophages as APC as in the legend to Fig. 2, and results are shown as cpm 599 
± SEM for triplicate wells. Controls were T cells and APC without peptide (0 in A and 600 
B), and 200 nM aggrecan (aggrecan in A), or 10 M unsubstituted peptide (89-103 in 601 
 27 
B). 602 
 603 
Figure 4. Hybridoma responses to citrullinated peptide 84-103. T cell hybridomas 604 
2G9 (a), 1271b (b), 1G2 (c) or 2D7 (d) were assayed as described in the legend to 605 
Fig. 2, except that 4 x 104 per well of the macrophage cell line J774A.1 were added as 606 
APC, and the antigen for the dose titrations were the native aggrecan peptide 84-103 607 
(93R95R), or the same peptide with citrulline substituted for the arginine at position 93 608 
(93cit95R), position 95 (93R95cit), or both (93cit95cit). 609 
 610 
Figure 5. T cell hybridoma responses to supernatants from degrading cartilage 611 
explants. T cell hybridomas 1271b (a,d), 1G2 (b,e) and 2D7 (c,f) were assayed for 612 
responses to (column A) supernatants collected from bovine cartilage explants after 613 
1, 5, 10 15 and 20 days of culture (showing one experiment of three), or (column B) 614 
supernatants collected from human articular cartilage explants after days 15 days of 615 
culture (showing supernatants from three different experiments HAC1-3). Preparation 616 
of supernatants is described in Materials and Methods, and supernatants were titrated 617 
and shown as percent of the total culture volume (the average protein concentration 618 
3.07 mg/ml for human and 1.5 mg/ml for bovine cartilage explant supernatants, of 619 
which the majority is known to be aggrecan (30)). Bone marrow derived macrophages 620 
were used as APC and results are shown as cpm ± SEM for triplicate wells. Controls 621 
included 1 M peptide 84-103 (84-103) and absence of peptide (0). 622 
623 
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Figure 1. Lymph node responses to peptide 84-103 and aggrecan  624 
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Figure 2. T cell hybridoma responses to peptide 84-103 and aggrecan  628 
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Figure 4. Hybridoma responses to citrullinated peptides. 639 
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Figure 5. T cell hybridoma responses to supernatants from cartilage explants 643 
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